Perspectives in MicroRNA Therapeutics - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Perspectives in MicroRNA Therapeutics
The authors provide further insight into microRNA biology, and the simplicity of anti-miR oligonucleotide drug delivery.

Pharmaceutical Technology
Volume 35, pp. a18-s24


Targeting pathways of human disease with microRNA-based drugs represents a novel and potentially powerful therapeutic approach. Recent data demonstrate not only that dysregulated microRNAs are associated with and can cause human disease, but that selective modulation through anti-miR intervention can provide therapeutic benefits. Anti-miR oligonucleotides can be easily administered through local or parenteral injection routes with sufficient uptake of the agent to achieve sustained target inhibition in tissues and organs without the need of formulation. Improvements in anti-miR chemical design and pharmacokinetic properties will allow further exploration of microRNA biology and broaden the utility of microRNA therapeutics.

Kevin Steffy, PhD,* is the global alliance manager, Charles Allerson, PhD, is the associate director of chemistry, and Balkrishen Bhat, PhD, is the senior director of chemistry, all at Regulus Therapeutics, 3545 John Hopkins Ct., San Diego, CA 92121, tel. 858.202.6321,

*To whom all correspondence should be addressed.


1. S.T. Crooke et al., "Mechanisms of Antisense Drug Action, an Introduction," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 3–47.

2. S.M. Elbashir et al., Nature 411 (6386), 494–498 (2001).

3. A. Jackson and P.S. Linsley, Discovery Medicine 9 (47), 311–318 (2010).

4. J. Krutzfeldt et al., Nature 438 (7068), 685–689 (2005).

5. D.P. Bartel, Cell 116 (2), 281–297 (2004).

6. E.C. Lai, Nat. Rev. Genet 30 (4), 363–364 (2002).

7. T. Thum et al., Nature 456 (7224), 980–984 (2008).

8. L. Ma et al., Nature 28 (4), 341–347 (2010).

9. R.E. Lanford et al., Science 327 (5962), 198–201 (2010).

10. P.P. Seth et al., J. Med. Chem. 52 (1), 10–13 (2009).

11. A.A. Levin, R. Zu, and R.S. Geary, "Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 183–215.

12. B. Monia et al. J. Biol. Chem. 268 (19), 14514–14522 (1993).

13. R.S. Geary, R. Zu, and A.A. Levin, "Pharmacokinetic/Pharmacodynamic Properties of Phosphorothioate 2'-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides in Animals and Man," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 306–326.

14. S.C. Semple et al., Nature Biotech. 28 (2), 172–176 (2010).

15. S.V. Dongen et al., Nature Methods 5 (12) 1023–1025 (2008).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here